ima901
Vaccineexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2007 (NCT00523159)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ima901
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01403285 | Phase 1 | Aug 1, 2011 | immatics Biotechnologies GmbH, National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT01265901 | Phase 3 | Dec 1, 2010 | immatics Biotechnologies GmbH, University of Cambridge, University of Rochester |
| NCT00785122 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2008 | immatics Biotechnologies GmbH |
| NCT00523159 | Phase 2 | May 1, 2007 | immatics Biotechnologies GmbH |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| immatics Biotechnologies GmbH | For profit | 4 | 4 | 3 | 2007 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2011 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2011 |
| University of Cambridge | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2010 |
5 organizations
Page 1 / 1